Abstract
This study aimed to measure the serum endocan level of patients with erectile dysfunction (ED) and to investigate the possible association between the Endothelial-specific molecule-1 (Endocan) level and ED. Twenty healthy and sixty-four male patients included in the study were divided into four groups: severe ED (19 patients), moderate ED (24 patients), mild ED (21 patients) and control group (20 healthy men). The erectile function of all the patients was evaluated using the International Index of Erectile Function-5 (IIEF-5) questionnaire. The body mass index (BMI) of each participant was determined, together with levels of fasting blood glucose, total testosterone, low- and high-density lipoprotein cholesterol, triglyceride and endocan in serum samples. No significant difference was found between the three ED groups and the control group in terms of the mean age, BMI and the levels of cholesterol and fasting blood glucose (P>0.05). The mean serum endocan level was found to 1.076±0.5, 0.674±0.40 and 0.671±0.3 ng ml−1 in the severe, moderate and mild ED groups, respectively. This indicated that the highest value was obtained from the severe ED group, and the difference between the severe ED group and the other groups was statistically significant. In the control group, the serum endocan level was 0.73±0.46 ng ml−1, which was significantly higher compared to the moderate and mild ED groups (P<0.05). The significant difference between the control and ED groups in terms of the serum endocan level can assist in the evaluation of endothelial pathologies in the etiology ED.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pohjantahti-Maaroos H, Palomaki A, Hartikainen J . Erectile dysfunction, physical activity and metabolic syndrome: differences in markers of atherosclerosis. BMC Cardiovasc Disord 2011; 11: 36–44.
Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr et al. Definitions/epidemiology/ risk factors for sexual dysfunction. J Sex Med 2010; 7: 1598–1607.
Shaeer O, Shaeer K . The Global Online Sexuality Survey (GOSS). Erectile dysfunction among Arabic-speaking Internet users in the Middle East. J Sex Med 2011; 8: 2152–2160.
Berrada S, Kadri N, Mechakra-Tahiri S, Nejjari C . Prevalence of erectile dysfunction and ts correlates: a population-based study in Morocco. Int J Impot Res 2003; 15: 1.
Meldrum DR, Gambone JC, Morris MA, Meldrum DA, Esposito K, Ignarro LJ . The link between erectile and cardiovascular health: the canary in the coal mine. Am J Cardiol 2011; 15: 599–606.
Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C . Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 2007; 52: 1590–1600.
Yao F, Huang Y, Zhang Y, Dong Y, Ma H, Deng C et al. Subclinical endothelial dysfunction and low-grade inflammation play roles in the development of erectile dysfunction in young men with low risk of coronary heart disease. Int J Androl 2012; 35: 653–659.
Menon P, Kocher ON, Aird WC . Endothelial cell specific molecule-1 (ESM-1), a novel secreted proteoglycan stimulates vascular smooth muscle cell proliferation and migration. Circulation 2011; 124: A15455.
Lee W, Ku S-K, Kim S-W, Bae J-S . Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol 2014; 229: 620–630.
Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R et al. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 2013; 73: 1097–1106.
Chen LY, Liu X, Wang SL, Qin CY . Over-expression of the endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res 2010; 38: 498–510.
Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M et al. Elevated serum levels of endocan in patients with Psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013; 169: 1066–1070.
Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T et al. Serum endocan levels as a marker of disease activity in patients with Behcet disease. J Am Acad Dermatol 2014; 70: 291–296.
Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M et al. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014; 65: 773–777.
Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M et al. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology 2014; 66: 727–731.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.
Champion HC, Bivalacqua TJ, Hyman AL, Ignarro LJ, Hellstrom WJ, Kadowitz PJ . Gene transfer of endothelial nitric oxide syntase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci USA 1999; 96: 11648–11652.
Ganz P, Vita JA . Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 2003; 108: 2049–2053.
Behrendt D, Ganz P . Endothelial function: from vascular biology to clinical applications. Am J Cardiol 2002; 90: 40–48.
Witztum JL, Steinberg D . Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785–1792.
Drakopoulou M, Toutouzas K, Stefanadi E, Tsiamis E, Tousoulis D, Stefanadis C . Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis 2009; 206: 335–339.
Morley JE, Korenman SG, Kaiser FE, Mooradian AD, Viosca SP . Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older men. Am J Med 1988; 84 (3 Pt 1): 445–448.
Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P et al. ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010; 121: 1439–1446.
Zakynthinos E, Pappa N . Inflammatory biomarkers in coronary artery disease. J Cardiol 2009; 53: 317–333.
Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M et al. Human endothelialcell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001; 167: 3099–3106.
Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006; 1765: 25–37.
Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyileten T et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014; 86: 1213–1220.
Wang X-S, Yang W, Luo T, Wang J-M, Jing Y-Y . Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomark 2015; 19: 124–127.
Lee G-K, Lee L-C, Chong E, Lee C-H, Teo S-G, Chia B-L et al. The longterm predictive value of the neutrophil-to-lymphocyte ratio in type 2 diabetic patients presenting with acute myocardial infarction. QJM 2012; 105: 1075–1082.
Yao F, Huang Y, Zhang Y, Dong Y, Ma H, Deng C et al. Subclinical endothelial dysfunction and low-grade inflammation play roles in the development of erectile dysfunction in young men with low risk of coronary heart disease. Int J Androl 2012; 35: 653–659.
Dong JY, Zhang YH . Qin LQ. Erectile dysfunction ana risk of cardiovascular disease meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58: 1378–1385.
Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM et al. A populationbased, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108–113.
Karabakan M, Bozkurt A, Gunay M, Aktas BK, Hirik E, Aydın M et al. Association between serum fetuin-A level and erectile function. Andrologia 2015; 48: 787–792.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Karabakan, M., Bozkurt, A., Akdemir, S. et al. Significance of serum endothelial cell specific molecule-1 (Endocan) level in patients with erectile dysfunction: a pilot study. Int J Impot Res 29, 175–178 (2017). https://doi.org/10.1038/ijir.2017.19
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijir.2017.19
This article is cited by
-
A new proof for the relationship between erectile dysfunction and atherosclerosis: fragmented QRS?
International Journal of Impotence Research (2020)
-
Aptamer-based search for correlates of plasma and serum water T2: implications for early metabolic dysregulation and metabolic syndrome
Biomarker Research (2018)
-
Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction?
International Urology and Nephrology (2018)